Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Zimmer Biomet Holdings, Inc. publishes a filing, an earnings call transcript or a press release.

Get ZBH alerts

About Paul Stellato

Paul Stellato is recorded as CFO at Zimmer Biomet Holdings, Inc. (ZBH) since April 28, 2026 and Chief Accounting Officer at Zimmer Biomet Holdings, Inc. (ZBH) since May 16, 2022. Zimmer Biomet Holdings, Inc. reported in an 8-K filed April 28, 2026 that Paul Stellato was appointed interim Chief Financial Officer, effective April 28, 2026. Zimmer Biomet Holdings, Inc. reported in an 8-K filed May 16, 2022 that Paul Stellato was appointed Vice President, Controller and Chief Accounting Officer. Zimmer Biomet Holdings, Inc. reported in an 8-K filed May 16, 2022 that Paul Stellato was appointed Vice President, Controller and Chief Accounting Officer, effective May 16, 2022. Paul Stellato has spoken on 1 earnings call across 1 company, most recently for Zimmer Biomet Holdings, Inc. on August 5, 2026. Zimmer Biomet Holdings, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Zimmer Biomet Holdings, Inc. includes Daniel Florin (CEO), Ivan Tornos (CEO, Chairman and Board Member), Christopher B. Begley (Chairman) and 7 others.

“In connection with Mr. Upadhyay's departure, Paul Stellato, Vice President, Controller and Chief Accounting Officer, has been appointed to act, along with continuing to serve in his current role, as the Company's interim Chief Financial Officer, effective upon Mr. Upadhyay's departure, until a permanent successor is named.”
Zimmer Biomet Holdings, Inc. Form 8-K, filed April 28, 2026 · Read the filing
“Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Paul Stellato as Vice President, Controller and Chief Accounting Officer.”
Zimmer Biomet Holdings, Inc. Form 8-K, filed May 16, 2022 · Read the filing

Paul Stellato on recent calls

“As Yvonne reviewed, we grew sales 4% on an organic constant currency basis in the second quarter, driven by strength in hips, high-growth segments of SET, and robotics.”
CFO, Zimmer Biomet Holdings, Inc. Q2 FY2026 Earnings Call ·

Affiliation history

Company network

Leadership on record at Zimmer Biomet Holdings, Inc.

Recent activity